The central problem the researchers set out to solve is a familiar one in oncology. Reactive oxygen species, or ROS, are powerful weapons against tumor cells because they can push cells into apoptosis, the well-known programmed suicide pathway, and into ferroptosis, a more recently discovered death mode driven by iron-dependent destruction of cell membranes. But tumors fight back. Cancer cells maintain an arsenal of antioxidant defenses, most notably high levels of the reducing molecule glutathione, which rapidly scavenges ROS before it can do lethal damage. Therapies that rely on a single death pathway are also vulnerable to resistance, since tumor cells can adapt and evade one route of killing. The team reasoned that attacking both apoptosis and ferroptosis simultaneously, while depleting the tumor’s glutathione shield, could overwhelm these defenses.

Each existing ROS-generating modality carries its own baggage. Chemodynamic therapy depends on endogenous hydrogen peroxide inside tumors, which is often too scarce to sustain ROS production. Photodynamic therapy uses light, but light penetrates only a few millimeters into tissue and oxygen is frequently lacking in tumor cores. Sonodynamic therapy, by contrast, uses ultrasound waves that travel deep into the body noninvasively and with a favorable safety profile, making it a natural partner for treating solid tumors buried far below the surface. The challenge was pairing it with a chemotherapy payload in a vehicle stable enough to circulate in blood yet responsive enough to unload its cargo precisely where it is needed.

PSCT answers that challenge with a covalent design. Rather than physically encapsulating drugs inside a carrier, the researchers chemically linked TCPP to one polymer backbone and CPT to another, creating two amphiphilic building blocks that self-assemble into uniform spherical nanoparticles. The two components are joined through disulfide bonds, chemical links that remain intact in the bloodstream but are cleaved by the abundant glutathione found inside tumor cells. This covalent strategy delivered a TCPP content of 35.8 percent in the polymer conjugate, exceeding the sub-30 percent loading typical of comparable TCPP-based platforms, and it minimized premature drug leakage during circulation. The finished nanoparticles measured about 140 nanometers in diameter with a Zeta potential of minus 28.6 millivolts, and they remained stable in storage and in blood-serum conditions for the durations required for intravenous use.

The release behavior confirmed the design logic. Under physiological conditions at neutral pH, cumulative TCPP leakage was only about 4 percent, indicating the payload stays locked in transit. But when the nanoparticles encountered a glutathione-rich, mildly acidic environment mimicking a tumor cell interior, they disassembled, swelling to roughly 209 nanometers, and released nearly 70 percent of their CPT cargo within about 80 hours. Once released, the two drugs execute a coordinated attack. CPT, a topoisomerase I inhibitor long used against breast, liver, and colorectal cancers, inflicts DNA damage that activates caspase enzymes and drives apoptosis. TCPP, energized by ultrasound, generates singlet oxygen that floods the cell with oxidative stress, depletes glutathione further, and pushes lipids in cell membranes toward peroxidation, the biochemical signature of ferroptosis.

In laboratory experiments with CT26 colorectal cancer cells, the combination proved decisively more lethal than either component alone. PSCT plus ultrasound showed an IC50 value of 1.1 micrograms per milliliter, compared with 5.9 for free CPT, 14.4 for TCPP with ultrasound, and 3.2 for the free drug combination. A Chou-Talalay combination index of 0.89, below the threshold of 1, formally confirmed synergy between the chemotherapy and the sonodynamic arm. Fluorescent probes revealed a surge of intracellular ROS and lipid peroxidation after treatment, and bio-electron microscopy captured the aftermath inside the cells: mitochondria that normally appear as elongated organelles with tidy internal cristae were swollen, vacuolated, and stripped of their cristae, morphological evidence of a direct assault on mitochondrial membranes by accumulated lipid peroxides.

Animal studies then tested whether the platform could find tumors and spare healthy tissue. Fluorescently labeled PSCT injected into tumor-bearing mice accumulated strongly at tumor sites, peaking at 24 hours, while a free dye control spread indiscriminately through the body. Ex vivo analysis showed tumor fluorescence far exceeding that of the heart, liver, spleen, lung, and kidney, confirming passive tumor targeting through the enhanced permeability and retention effect. Hemolysis tests showed rupture of red blood cells below 5 percent at all concentrations, and organ histology plus blood chemistry found no liver or kidney damage at the chosen therapeutic dose of 6 milligrams per kilogram. Pharmacokinetic measurements underscored the benefit of the nanocarrier: peak plasma concentration of CPT rose roughly elevenfold compared with free drug, and the 24-hour exposure area increased from 2.52 to 58.61 milligram-hours per liter.

Therapeutic results in the mouse model were dramatic. With ultrasound applied at 1 megahertz and 1.5 watts per square centimeter for five minutes, six hours after each injection, tumor growth in the PSCT plus ultrasound group slowed to a near standstill, yielding a tumor inhibition rate of 85.19 percent. Temperature monitoring showed tumor heating of only about 1.3 degrees Celsius, well below the threshold for thermal damage, confirming that the effect came from ROS generation rather than hyperthermia. Body weight remained stable throughout treatment, organ staining revealed no pathological changes, and serum markers of liver and kidney function stayed within normal ranges. A 14-day repeat-dose toxicity study reinforced the safety picture, though the authors note that higher-dose repeated administration still warrants evaluation.

To understand why the therapy worked so well, the team turned to RNA sequencing of treated cells. The analysis identified 4,107 differentially expressed genes and revealed enrichment of ferroptosis and apoptosis pathways alongside upstream signaling networks including MAPK, PI3K-Akt, p53, and Ras. Anti-ferroptosis genes such as Gpx4, Slc7a11, and Slc3a2 were downregulated while pro-ferroptosis genes Acsl4 and Trp53 rose, and pro-apoptotic genes including Bax and Casp1 climbed as the anti-apoptotic Bcl2 fell. Computational docking suggested CPT can bind caspase-3 with a favorable binding energy of minus 7.6 kilocalories per mole, a prediction supported by stable 100-nanosecond molecular dynamics simulations, though the authors caution this requires biochemical validation. Western blots and tumor immunofluorescence confirmed the protein-level changes: cleaved caspase-3, the executioner of apoptosis, increased sharply, while GPX4, the enzyme that normally defends membranes against ferroptosis, dropped substantially. Notably, both a ferroptosis inhibitor and a caspase blocker partially rescued cell viability to similar degrees, indicating that neither pathway alone accounts for the killing.

The broader significance of the work lies in its demonstration that tumor resistance can be attacked at the level of cell death programming itself. By coupling a deep-penetrating physical trigger with a tumor-specific chemical trigger, and by forcing cancer cells to run two lethal programs simultaneously, PSCT offers a template for therapies that leave tumor cells no single escape route. The researchers suggest that even if tumor cells develop adaptive defenses against one death pathway, the complementary pathway continues to exert cytotoxic pressure, a strategy that could prove valuable against multidrug-resistant malignancies. While clinical translation will require further optimization of dosing, irradiation timing, and safety testing at higher doses, the study presents a compelling case that reprogramming how tumor cells die, rather than merely how they are damaged, may be the key to treating deep-seated solid tumors with precision and minimal toxicity.

Subject of Research: A glutathione-responsive polymeric nanoplatform combining sonodynamic therapy and chemotherapy that induces dual ferroptosis-apoptosis tumor cell death

Article Title: CPT-TCPP polymeric nanoplatform for sonodynamic-chemotherapy synergistic tumor therapy through ferroptosis-apoptosis dual cell death reprogramming

Article References: Wang, L., Zhang, Z., Liu, Q., Zhang, H., Peng, J., & Wang, D. (2026). CPT-TCPP polymeric nanoplatform for sonodynamic-chemotherapy synergistic tumor therapy through ferroptosis-apoptosis dual cell death reprogramming. Materials Today Bio, 41, Article 103699. https://doi.org/10.1016/j.mtbio.2026.103699

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103699

Keywords: sonodynamic therapy, chemotherapy, camptothecin, TCPP, ferroptosis, apoptosis, nanoparticles, glutathione-responsive, reactive oxygen species, tumor microenvironment, colorectal cancer, drug delivery